AquaBounty Technologies is confident about the future despite net losses rising to US$5.3million (€3.56 million) in the year to the end of December up from US$4.8 million (€3.22 million) last time. AquaBounty a biotechnology company focussed on enhancing productivity in the aquaculture market had cash and cash equivalents of US$2.6 million (€1.7 million) at the year-end up from US$1.2 million (€0.807 million) in 2009.
AquaBounty said 2010 was a pivotal year when it achieved key milestones towards United States Food and Drug Administration approval for AquAdvantage Salmon. CEO Ron Stotish said: "I remain confident that this will soon be forthcoming, which will enable us to move into the commercial phase of development. Read more ...
This blog is written by Martin Little The Aquaculturists, published and supported by the International Aquafeed Magazine from Perendale Publishers
AquaBounty said 2010 was a pivotal year when it achieved key milestones towards United States Food and Drug Administration approval for AquAdvantage Salmon. CEO Ron Stotish said: "I remain confident that this will soon be forthcoming, which will enable us to move into the commercial phase of development. Read more ...
This blog is written by Martin Little The Aquaculturists, published and supported by the International Aquafeed Magazine from Perendale Publishers
No comments:
Post a Comment